Orion posts mixed June results as overseas growth offsets domestic slump
The snack maker's consolidated sales rose on strong performance in China and Russia, even as operating profit in its home market fell amid rising costs.

Orion reported mixed financial results for June, with consolidated sales climbing to 335 billion won ($234 million) while domestic operating earnings slipped due to a challenging home market environment.
The company said Thursday that total revenue for the month rose from the previous year, driven by robust expansion in its Chinese and Russian subsidiaries that more than compensated for slower growth in South Korea.
Sales in China jumped 28.6 percent on-year to 124 billion won ($86.7 million), with the unit's operating profit swelling 33.5 percent. Momentum was even stronger in Russia, where revenue surged 42.4 percent to 34.9 billion won ($24.4 million) and operating income climbed 64.3 percent.
In contrast, the domestic business faced headwinds from weak consumer demand and higher input costs, leading to an 11.7 percent drop in operating profit despite a 9.6 percent increase in local sales.
An Orion official attributed the domestic pressure to a decline in sales channels and rising prices for major raw materials.
Looking ahead, the company expects growth to accelerate in the second half of the year as preemptive investments in production and logistics facilities begin to expand supply capacity. "Preemptive investments in production and logistics facilities at home and abroad will expand supply volumes in the second half, further accelerating growth," an Orion official said.
What this article is based on
Every fact in this article can be checked against the primary documents below.
- Regulatory filing오리온 연결재무제표기준영업(잠정)실적(공정공시)· DART· accessed Aug. 28, 2026
- Regulatory filing주력 사업· DART· accessed Aug. 4, 2026
- Other[발언] 오리온 관계자· orionworld.com· accessed Aug. 4, 2026
© New Era Korea Daily. All rights reserved.
More in Companies
- Kumho Engineering wins 145 billion won rail contract in North Gyeongsang
- HLB to absorb HLB Life Science in all-stock merger to unify rivoceranib rights
- L&F raises 30.3 billion won in perpetual convertible bonds for cathode expansion
- Meritz Financial third-quarter revenue jumps 78% as net income slips
- Phionx to raise 13.6 billion won via rights issue and convertible bonds